When does Adbry’s patent expire?
Adbry (tralokinumab) is still protected by patent rights, but the exact expiration date depends on which specific patent (and which country) applies. Patent “expiration” can also differ from regulatory exclusivity dates (such as additional protection granted to delay generic/biosimilar entry), so the relevant date for market availability is not always the same as the first patent listed in a database.
Because the timing varies by jurisdiction and by the particular patent family, you need the country (for example, US vs. EU) to determine the precise expiration date for Adbry’s patents.
How to find the exact patent expiration date for Adbry (by country)
If you tell me the market you care about (US, EU, UK, Canada, etc.), I can narrow it down using:
- Patent family filings for tralokinumab (what claims they cover, and when they were filed).
- Whether any patents are later amended, extended, or subject to regulatory “patent term adjustment/extension” in that country.
- Whether a later “blocking” patent is expected to keep biosimilars off the market even after earlier patents expire.
Is patent expiry the same as biosimilar or generic entry timing?
Not always. Even after some patents expire, additional protections may still delay competition, including:
- Other active patents covering formulation, dosing, indications, or specific claim scopes.
- Regulatory exclusivity periods (which can extend beyond the first patent expiration, depending on the jurisdiction).
So, the “patent expiry” date you might look up may not match the date a biosimilar can launch.
What I need from you to give the exact date
Which country’s expiration date do you mean—United States, European Union (or a specific EU country), or another market?